No significant difference between ceftriaxone and cefotaxime in the emergence of antibiotic resistance in the gut microbiota of hospitalized patients: A pilot study
Background: Ceftriaxone and cefotaxime share a similar antibacterial spectrum and similar indications but have different pharmacokinetic characteristics. Ceftriaxone is administered once daily and 40% of its clearance is by biliary elimination, whereas cefotaxime requires three administrations per d...
Main Authors: | , , , , , , , , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2021-03-01
|
Series: | International Journal of Infectious Diseases |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S1201971221000357 |
id |
doaj-aaa0cdaed1a845d4a32c7fe81069731f |
---|---|
record_format |
Article |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Benoît Pilmis Olivier Jiang Assaf Mizrahi Jean-Claude Nguyen Van Julie Lourtet-Hascoët Olivier Voisin Erwan Le Lorc’h Sidonie Hubert Elodie Ménage Philippe Azria Marie-Françoise Borie Annabelle Mahé Jean-Jacques Mourad Eloïse Trabattoni Olivier Ganansia Jean-Ralph Zahar Alban Le Monnier |
spellingShingle |
Benoît Pilmis Olivier Jiang Assaf Mizrahi Jean-Claude Nguyen Van Julie Lourtet-Hascoët Olivier Voisin Erwan Le Lorc’h Sidonie Hubert Elodie Ménage Philippe Azria Marie-Françoise Borie Annabelle Mahé Jean-Jacques Mourad Eloïse Trabattoni Olivier Ganansia Jean-Ralph Zahar Alban Le Monnier No significant difference between ceftriaxone and cefotaxime in the emergence of antibiotic resistance in the gut microbiota of hospitalized patients: A pilot study International Journal of Infectious Diseases Gut microbiota Third generation cephalosporin Extended spectrum beta-lactamase |
author_facet |
Benoît Pilmis Olivier Jiang Assaf Mizrahi Jean-Claude Nguyen Van Julie Lourtet-Hascoët Olivier Voisin Erwan Le Lorc’h Sidonie Hubert Elodie Ménage Philippe Azria Marie-Françoise Borie Annabelle Mahé Jean-Jacques Mourad Eloïse Trabattoni Olivier Ganansia Jean-Ralph Zahar Alban Le Monnier |
author_sort |
Benoît Pilmis |
title |
No significant difference between ceftriaxone and cefotaxime in the emergence of antibiotic resistance in the gut microbiota of hospitalized patients: A pilot study |
title_short |
No significant difference between ceftriaxone and cefotaxime in the emergence of antibiotic resistance in the gut microbiota of hospitalized patients: A pilot study |
title_full |
No significant difference between ceftriaxone and cefotaxime in the emergence of antibiotic resistance in the gut microbiota of hospitalized patients: A pilot study |
title_fullStr |
No significant difference between ceftriaxone and cefotaxime in the emergence of antibiotic resistance in the gut microbiota of hospitalized patients: A pilot study |
title_full_unstemmed |
No significant difference between ceftriaxone and cefotaxime in the emergence of antibiotic resistance in the gut microbiota of hospitalized patients: A pilot study |
title_sort |
no significant difference between ceftriaxone and cefotaxime in the emergence of antibiotic resistance in the gut microbiota of hospitalized patients: a pilot study |
publisher |
Elsevier |
series |
International Journal of Infectious Diseases |
issn |
1201-9712 |
publishDate |
2021-03-01 |
description |
Background: Ceftriaxone and cefotaxime share a similar antibacterial spectrum and similar indications but have different pharmacokinetic characteristics. Ceftriaxone is administered once daily and 40% of its clearance is by biliary elimination, whereas cefotaxime requires three administrations per day and shows less than 10% biliary elimination. The high biliary elimination of ceftriaxone suggests a greater impact of this antibiotic on the gut microbiota than cefotaxime. The objective of this study was to compare the impact of ceftriaxone and cefotaxime on the gut microbiota. Methods: A prospective clinical trial was performed that included 55 patients treated with intravenous ceftriaxone (1 g/24 h) or cefotaxime (1 g/8 h) for at least 3 days. Three fresh stool samples were collected from each patient (days 0, 3, and 7 or at the end of intravenous treatment) to assess the emergence of third-generation cephalosporin (3GC)-resistant Enterobacteriaceae, carbapenem-resistant Enterobacteriaceae, Pseudomonas aeruginosa, toxigenic Clostridioides difficile, and vancomycin-resistant enterococci. Results: The emergence of 3GC-resistant gram-negative enteric bacilli (Enterobacteriaceae) (5.9% vs 4.7%, p > 0.99), Enterococcus spp, and non-commensal microorganisms did not differ significantly between the groups. Both antibiotics reduced the counts of total gram-negative enteric bacilli and decreased the cultivable diversity of the microbiota, but the differences between the groups were not significant. Conclusion: No significant difference was observed between ceftriaxone and cefotaxime in terms of the emergence of resistance. |
topic |
Gut microbiota Third generation cephalosporin Extended spectrum beta-lactamase |
url |
http://www.sciencedirect.com/science/article/pii/S1201971221000357 |
work_keys_str_mv |
AT benoitpilmis nosignificantdifferencebetweenceftriaxoneandcefotaximeintheemergenceofantibioticresistanceinthegutmicrobiotaofhospitalizedpatientsapilotstudy AT olivierjiang nosignificantdifferencebetweenceftriaxoneandcefotaximeintheemergenceofantibioticresistanceinthegutmicrobiotaofhospitalizedpatientsapilotstudy AT assafmizrahi nosignificantdifferencebetweenceftriaxoneandcefotaximeintheemergenceofantibioticresistanceinthegutmicrobiotaofhospitalizedpatientsapilotstudy AT jeanclaudenguyenvan nosignificantdifferencebetweenceftriaxoneandcefotaximeintheemergenceofantibioticresistanceinthegutmicrobiotaofhospitalizedpatientsapilotstudy AT julielourtethascoet nosignificantdifferencebetweenceftriaxoneandcefotaximeintheemergenceofantibioticresistanceinthegutmicrobiotaofhospitalizedpatientsapilotstudy AT oliviervoisin nosignificantdifferencebetweenceftriaxoneandcefotaximeintheemergenceofantibioticresistanceinthegutmicrobiotaofhospitalizedpatientsapilotstudy AT erwanlelorch nosignificantdifferencebetweenceftriaxoneandcefotaximeintheemergenceofantibioticresistanceinthegutmicrobiotaofhospitalizedpatientsapilotstudy AT sidoniehubert nosignificantdifferencebetweenceftriaxoneandcefotaximeintheemergenceofantibioticresistanceinthegutmicrobiotaofhospitalizedpatientsapilotstudy AT elodiemenage nosignificantdifferencebetweenceftriaxoneandcefotaximeintheemergenceofantibioticresistanceinthegutmicrobiotaofhospitalizedpatientsapilotstudy AT philippeazria nosignificantdifferencebetweenceftriaxoneandcefotaximeintheemergenceofantibioticresistanceinthegutmicrobiotaofhospitalizedpatientsapilotstudy AT mariefrancoiseborie nosignificantdifferencebetweenceftriaxoneandcefotaximeintheemergenceofantibioticresistanceinthegutmicrobiotaofhospitalizedpatientsapilotstudy AT annabellemahe nosignificantdifferencebetweenceftriaxoneandcefotaximeintheemergenceofantibioticresistanceinthegutmicrobiotaofhospitalizedpatientsapilotstudy AT jeanjacquesmourad nosignificantdifferencebetweenceftriaxoneandcefotaximeintheemergenceofantibioticresistanceinthegutmicrobiotaofhospitalizedpatientsapilotstudy AT eloisetrabattoni nosignificantdifferencebetweenceftriaxoneandcefotaximeintheemergenceofantibioticresistanceinthegutmicrobiotaofhospitalizedpatientsapilotstudy AT olivierganansia nosignificantdifferencebetweenceftriaxoneandcefotaximeintheemergenceofantibioticresistanceinthegutmicrobiotaofhospitalizedpatientsapilotstudy AT jeanralphzahar nosignificantdifferencebetweenceftriaxoneandcefotaximeintheemergenceofantibioticresistanceinthegutmicrobiotaofhospitalizedpatientsapilotstudy AT albanlemonnier nosignificantdifferencebetweenceftriaxoneandcefotaximeintheemergenceofantibioticresistanceinthegutmicrobiotaofhospitalizedpatientsapilotstudy |
_version_ |
1724201409454276608 |
spelling |
doaj-aaa0cdaed1a845d4a32c7fe81069731f2021-03-27T04:25:55ZengElsevierInternational Journal of Infectious Diseases1201-97122021-03-01104617623No significant difference between ceftriaxone and cefotaxime in the emergence of antibiotic resistance in the gut microbiota of hospitalized patients: A pilot studyBenoît Pilmis0Olivier Jiang1Assaf Mizrahi2Jean-Claude Nguyen Van3Julie Lourtet-Hascoët4Olivier Voisin5Erwan Le Lorc’h6Sidonie Hubert7Elodie Ménage8Philippe Azria9Marie-Françoise Borie10Annabelle Mahé11Jean-Jacques Mourad12Eloïse Trabattoni13Olivier Ganansia14Jean-Ralph Zahar15Alban Le Monnier16Équipe Mobile de Microbiologie Clinique, Groupe Hospitalier Paris Saint-Joseph, Paris, France; Service de Maladies Infectieuses et Tropicales, Hôpital Necker–Enfants Malades, Paris, France; Institut Micalis, UMR 1319, Université Paris-Saclay INRAe, AgroParisTech, Chatenay-Malabry, France; Corresponding author at: Équipe Mobile de Microbiologie Clinique, Groupe Hospitalier Paris Saint-Joseph, 185 rue Raymond, Losserand, 75014 Paris, France.Service de Microbiologie Clinique, Groupe Hospitalier Paris Saint-Joseph, Paris, FranceInstitut Micalis, UMR 1319, Université Paris-Saclay INRAe, AgroParisTech, Chatenay-Malabry, France; Service de Microbiologie Clinique, Groupe Hospitalier Paris Saint-Joseph, Paris, FranceService de Microbiologie Clinique, Groupe Hospitalier Paris Saint-Joseph, Paris, FranceService de Microbiologie Clinique, Groupe Hospitalier Paris Saint-Joseph, Paris, FranceService de Médecine Interne, Groupe Hospitalier Paris Saint-Joseph, Paris, FranceService de Médecine Interne, Groupe Hospitalier Paris Saint-Joseph, Paris, FranceService de Médecine Interne, Groupe Hospitalier Paris Saint-Joseph, Paris, FranceService de Médecine Interne, Groupe Hospitalier Paris Saint-Joseph, Paris, FranceService de Médecine Interne, Groupe Hospitalier Paris Saint-Joseph, Paris, FranceService de Médecine Interne, Groupe Hospitalier Paris Saint-Joseph, Paris, FranceService de Médecine Interne, Groupe Hospitalier Paris Saint-Joseph, Paris, FranceService de Médecine Interne, Groupe Hospitalier Paris Saint-Joseph, Paris, FranceService d’Accueil des Urgences, Groupe Hospitalier Paris Saint-Joseph, Paris, FranceService d’Accueil des Urgences, Groupe Hospitalier Paris Saint-Joseph, Paris, FranceIAME, UMR 1137, Université Paris 13, Sorbonne Paris Cité, France; Service de Microbiologie Clinique et Unité de Contrôle et de Prévention du Risque Infectieux, Groupe Hospitalier Paris Seine Saint-Denis, AP-HP, Bobigny, FranceInstitut Micalis, UMR 1319, Université Paris-Saclay INRAe, AgroParisTech, Chatenay-Malabry, France; Service de Microbiologie Clinique, Groupe Hospitalier Paris Saint-Joseph, Paris, FranceBackground: Ceftriaxone and cefotaxime share a similar antibacterial spectrum and similar indications but have different pharmacokinetic characteristics. Ceftriaxone is administered once daily and 40% of its clearance is by biliary elimination, whereas cefotaxime requires three administrations per day and shows less than 10% biliary elimination. The high biliary elimination of ceftriaxone suggests a greater impact of this antibiotic on the gut microbiota than cefotaxime. The objective of this study was to compare the impact of ceftriaxone and cefotaxime on the gut microbiota. Methods: A prospective clinical trial was performed that included 55 patients treated with intravenous ceftriaxone (1 g/24 h) or cefotaxime (1 g/8 h) for at least 3 days. Three fresh stool samples were collected from each patient (days 0, 3, and 7 or at the end of intravenous treatment) to assess the emergence of third-generation cephalosporin (3GC)-resistant Enterobacteriaceae, carbapenem-resistant Enterobacteriaceae, Pseudomonas aeruginosa, toxigenic Clostridioides difficile, and vancomycin-resistant enterococci. Results: The emergence of 3GC-resistant gram-negative enteric bacilli (Enterobacteriaceae) (5.9% vs 4.7%, p > 0.99), Enterococcus spp, and non-commensal microorganisms did not differ significantly between the groups. Both antibiotics reduced the counts of total gram-negative enteric bacilli and decreased the cultivable diversity of the microbiota, but the differences between the groups were not significant. Conclusion: No significant difference was observed between ceftriaxone and cefotaxime in terms of the emergence of resistance.http://www.sciencedirect.com/science/article/pii/S1201971221000357Gut microbiotaThird generation cephalosporinExtended spectrum beta-lactamase |